Featured Stocks
Uranium Energy Corp. (UEC)
Uranium Energy Corp. (AMEX:UEC) is a U.S.-based exploration and development company focused on near-term uranium production in the U.S. The company’s operations are managed by professionals who have earned a reputable profile through many decades of hands-on experience in the key facets of uranium exploration, development and mining.
Uranium Energy controls one of the largest databases of historic uranium exploration and development in the nation. Using this knowledge base, the company has acquired and is advancing exploration properties of merit throughout the southwestern U.S., a region known as being the most concentrated area for uranium mining in the United States.
The Company’s fully licensed and permitted Hobson processing facility is central to all of its projects in South Texas. Well financed to execute on its key programs, Uranium Energy’s Palangana is-situ recovery project is fully permitted, and its Goliad in-situ recovery project is in the final stages of mine permitting for production.
The company’s strategy of acquiring exploration databases and leveraging those databases to generate acquisition targets has proven to be effective thus far. With plans to continue aggressively pursuing this strategy, Uranium Energy Corp is well positioned to capitalize on the world’s first significant alternative energy boom.
Key statistics (7/26/10):
Market cap: $147.59 Million
Current Ratio: 24.2 versus industry average of 3.8
Quick Ratio: 24.2 versus industry average of 3.2
Insider Holding Percentage: 32.20%
Cash and Equivalents: $25.9 Million
Total Assets: $52.2 Million
Total Shares Outstanding: 60,644,475
Debt/Equity Ratio: 0.0 versus industry average of 0.45
Recent News
Servotronics, Inc. (SVT)
Servotronics, Inc. has established a reputation for its design, development, and manufacture of high quality components, systems and sub-systems for use wherever precise control, reliability and cost containment are required. The company’s products include servocontrol valves, torque motors, actuators, check valves, pressure regulators, metallic seals and many other products which are used in a wide range of applications and industries.
Servotronics is committed to delivering customer satisfaction by meeting and exceeding their product requirements for value, quality, reliability, and on-time deliveries. The company views all challenges as achievement based opportunities for continuous improvement. Viewing itself as a team player, Servotronics’ synergistically combines its employees’ expertise, efforts and support to create the cutting edge of technology and value.
Currently the company trades at a P/E of 8.5 and Market Cap of $19.53 Million. With annual sales of $32.45 Million, the company trades at a Price/Sales Ratio of only 0.69. Over the past five years, annual net income has grown at an average of 20.99% versus the industry average of 20.45%.
For the first six months of this year, the company generated net income of $1,401,000 (or $0.66 per share diluted) on revenues of $16,087,000. This compares to net income of $835,000 (or $0.41 per share diluted) on revenues of $16,644,000 during the same six month period of 2009, an approximate 68% increase in net income.
As of last report, Servotronics had $28.1 Million in assets, $3.3 Million in current liabilities and $3.3 Million in long-term debt. Shareholder equity totals $20.5 Million providing a solid Debt/Equity Ratio of 0.20. The company also boasts a respectable 12.6% Return on Equity, 9.0% Return on Assets and 10.4% Return on Capital.
Key statistics (8/26/10):
Market cap: $19.53 Million
P/E Ratio: 8.5 versus industry average of 17.4
P/S Ratio: 0.69 versus industry average of 1.62
Price/Cash Flow Ratio: 7.20 versus industry average of 43.80
Debt/Equity Ratio: 0.20 versus industry average of 0.45
Current Ratio: 6.5 versus industry average of 2.0
Quick Ratio: 3.2 versus industry average of 1.6
Book Value/Share: $10.45 versus current market price of $9.96
Return on Equity: 12.6% versus industry average of 14.8%
Return on Assets: 9.0% versus industry average of 6.9%
Return on Capital: 10.4% versus industry average of 11.2%
Inventory Turnover: 2.1 versus industry average of 5.1
Recent News
Five Star Quality Care, Inc. (FVE)
Five Star Quality Care, Inc. is a national healthcare and senior living services provider focused on building a solid financial base by carefully managing assets, resulting in a better bottom-line and enhanced resident care. With more than 21,000 employees in 230 locations nationwide, the company operates through three major divisions: Five Star Senior Living, Five Star Rehabilitation Services, and Five Star Pharmacy Services.
The Five Star Senior Living division includes more than 200 Independent Living and Assisted Living facilities, Skilled Health Care facilities, and Continuing Care Retirement Communities. Through its Rehabilitation Services division, Five Star operates rehabilitation hospitals and outpatient health rehabilitation clinics. Through its Pharmacy Services division, Five Star operates institutional pharmacies across the country.
There is much opportunity for the company to grow as the aging U.S. population increases demand for independent living properties, assisted living communities, skilled nursing facilities, pharmacies and rehabilitation services. In addition to capitalizing on this industry growth, the company aims to improve profitability of its existing operations by increasing revenues and improving margins. Five Star is also utilizing a proven acquisition strategy for growth and continues to seek additional areas of expansion.
With more than a billion in annual revenues, the company trades at a market cap of $161.8 million, providing a price to sales ratio of only 0.13! Few investors foresee a decline in stock price coming any time soon with less than 3% of the float reportedly shorted. Two analysts currently believe the company is a “Buy”, while one other believes it’s a “Hold”. Currently 48.20% of the shares outstanding are held by institutions while 11.81% are held by insiders.
Most experienced investors would assume at this point that Five Star must have a poor balance sheet and/or revenues are declining, but the company actually has a solid balance sheet with $25.7 million in cash, and revenues have grown at an average of 14.81% the past five years.
Key statistics (8/26/10):
Market cap: $161.83 Million
P/E Ratio: 9.0 versus industry average of 8.9
P/S Ratio: 0.13 versus industry average of 0.75
Price/Cash Flow Ratio: 4.7 versus industry average of 10.9
Debt/Equity Ratio: 0.36 versus industry average of 2.37
Current Ratio: 1.1 versus industry average of 1.1
Quick Ratio: 1.1 versus industry average of 1.1
Book Value/Share: $4.27 versus current market price of $4.53
Return on Equity: 12.8% versus industry average of -0.8%
Return on Assets: 4.4% versus industry average of 2.1%
Return on Capital: 7.4% versus industry average of 2.8%
Receivable Turnover: 19.8 versus industry average of 25.1
Recent News
Metropolitan Health Networks, Inc. (MDF)
Metropolitan Health Networks, Inc. provides comprehensive health care services to people with Medicare in Florida. The company currently cares for approximately 35,000 customers in 18 counties in South and Central Florida. Metropolitan Health’s team of physicians, professionals, and associates are committed to serving customers with the highest standards of medical treatment and personal service. The company aims to always exceed expectations.
For decades, Florida has been a highly attractive and rapidly growing market. In 2005, the state’s population of those 65 and older was 3.0 million and was forecasted to increase to 3.4 million by 2010 and to 4.7 million by 2020. Florida is also the second largest Medicare population in the U.S. with an estimated 3.2 million eligible beneficiaries. In addition to rising demand, the company intends to continue growing by investing in the development of healthcare provider networks in other counties.
The company has outstanding financial stability with a debt/equity ratio of just 0.01. As of last report, the company held $8.2 million in cash and cash equivalents, and $52.7 million in other assets. Total current and long-term liabilities were reported at $6.7 million. Metropolitan Health also boasts a respectable 36.4% Return on Assets (ROA) and 40.6% Return on Equity (ROE).
Generating $362.5 million in sales, the company trades at a market cap of only $141.09 million. Insiders own approximately 27.38% of shares outstanding while institutions hold 32.20%. Investor sentiment is almost entirely bullish with less than 4% of the float sold short. Currently, one analyst rates the company a “Strong Buy” and another rates it a “Buy”.
Key statistics (8/26/10):
Market cap: $141.09 Million
P/E Ratio: 7.5 versus industry average of 7.4
P/S Ratio: 0.40 versus industry average of 0.35
Price/Cash Flow Ratio: 6.90 versus industry average of 18.7
Debt/Equity Ratio: 0.01 versus industry average of 0.39
Current Ratio: 7.4 versus industry average of 0.6
Quick Ratio: 7.4 versus industry average of 0.6
Book Value/Share: $1.33 versus current market price of $3.48
Return on Equity: 40.6% versus industry average of 18.1%
Return on Assets: 36.4% versus industry average of 6.8%
Return on Capital: 40.1% versus industry average of 6.3%
5-Year average ROE: 19.2% versus industry average of 17.0%
Recent News
Ness Technologies, Inc. (NSTC)
Ness Technologies, Inc. provides Information Technology (IT) business services and solutions to more than 500 clients in the commercial, industrial and government sectors. The company is known for its specialized expertise in software product engineering; system integration, application development and consulting; and software distribution. The company delivers its services and solutions through offices located in 18 different countries with a work force of approximately 8,000 experienced professionals.
Ness Technologies has formed strategic partnerships with many leading global software and infrastructure vendors to capitalize on a wide array of technologies and innovation. The company continuously evaluates and pursues other potential partners to deliver the most effective and advanced solutions to its clients. By achieving the highest level of certification with many of its partners, Ness Technologies has been able to leverage its early access to new product offerings to influence the development of new products and offerings.
Despite economic turbulence, the company’s balance sheet remains strong. As of last report, the company held $35.0 million in cash and cash equivalents, and $627.5 million in other assets. Total current and long-term liabilities were reported at $332.4 million. Stockholders’ equity totals approximately $330.2 million providing a book value per share of $8.69, which is significantly higher than the current market price.
For the second quarter of 2010, Ness Technologies reported revenues of $139.7 million, an increase of 10% from last year. The company said it continues to expect top line revenue growth and margin expansion throughout the rest of the year, with third quarter results in line with second quarter results, and fourth quarter results significantly better than third quarter results.
Currently, 2.16% of the shares outstanding are held by insiders and 68.50% are held by institutions. Two analysts believe the company is a “Strong Buy, two believe it’s a “Buy”, and one believes it’s a “Hold”. Next year analysts expect earnings per share of $0.57 compared to this year’s $0.43. Next year’s revenues are anticipated to total $604.4 million versus this year’s $565.5 million.
Key statistics (8/26/10):
Market cap: $161.5 Million
P/S Ratio: 0.32 versus industry average of 1.93
5-Year Avg. Sales Growth of 12.44% versus industry average of 14.81%
5-Year Avg. Gross Margin of 27.6% versus industry average of 26.8%
Debt/Equity Ratio: 0.24 versus industry average of 0.25
Current Ratio: 1.3 versus industry average of 2.7
Quick Ratio: 1.3 versus industry average of 2.7
Book Value/Share: $8.69 versus current market price of $4.25
Recent News
TraderPower Featured Stocks
Top Small Cap Market News
- PostRock (PSTR) Announces $60 Million Investment by White Deer Energy
- Orexigen® Therapeutics (OREX) and Takeda Enter Into Partnership to Commercialize Contrave® in North America
- Sycamore Networks, Inc. (SCMR) Reports Fourth Quarter and Fiscal Year 2010 Financial Results
- Rexahn Pharmaceuticals (RNN) Announces Publication of New Preclinical Research Data for Novel Anticancer Compound RX-8243
- Acasti Pharma Inc. (NEPT) Reports Positive Impacts on Cardiometabolic Associated Disorders
